Project: A FAS ligand hexameric (APO010) and companion diagnostics in the immunotherapy of multiple myeloma
We aim to advance a new immunotherapy drug (APO010) to clinical proof of concept in the treatment of multiple myeloma (MM) by using an advanced Drug Response Predictor (DRP) analysis, based on genomic information combined with clinical tumor biology and clinical correlates in a systems biology network, as a Companion Diagnostic (CDx). APO010-sensitive patients will undergo a prospective clinical trial of APO010 exploring early efficacy signals and tolerability in a highly selected patient group
Acronym | APO010-in-selected-MM (Reference Number: 10480) |
Duration | 01/03/2016 - 01/03/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |